Known in scientific circles for its role in gastric protection and gastrointestinal support, BPC-157 is being explored for its potential to support gut lining strength, digestion, and balance in the microbiome ecosystem
Safety Profile: What Clinical Trials Actually Documented Across six clinical trials involving approximately 900 participants, AOD-9604 produced no treatment-related serious adverse events, no immunogenic response, no IGF-1 elevation, and no adverse cardiovascular or metabolic signals
First month of usage of Tirzepatide Injections
BPC-157 / TB-500 is a research peptide blend combining two well-studied synthetic peptides: Body Protection Compound-157 (BPC-157) and Thymosin Beta-4 fragment TB-500. BPC-157 is a stable gastric pentadecapeptide originally derived from human gastric juice, while TB-500 is a synthetic peptide modeled after the naturally occurring thymosin beta-4. Together, this blend is formulated for laboratory research focused on tissue repair, angiogenesis, and cellular regeneration pathways
